The UAE has announced the start of production in the country of the COVID-19 vaccine.
The vaccine, Hayat-Vax, which means life in Arabic, will be manufactured as part of a joint venture with Sinopharm CNBG, one of the largest pharmaceutical companies that have produced over 100 million doses of the COVID-19 vaccine globally as well as G42, the leading technology company in Abu Dhabi.
Hayat-Vax uses the same inactivated vaccine used in the Sinopharm vaccine through which testing has shown 79.34% efficacy.
The UAE made vaccine will be available across 205 centres. Currently, 52% of the population has been vaccinated.
A purpose-built research and development hub for life sciences, biotechnology and vaccine production has also been launched in Abu Dhabi and is being set up by KIZAD.
The new vaccination plant in KIZAD will be operational this year. Hayat-Vax is currently in production with an initial capacity of 2 million doses per month along with its partner, Julphar.
Over 43,000 volunteers participating from over 125 nationalities participated last year in the 4Humanity clinical trial of the inactivated vaccine in collaboration with Sinopharm CNBG and G42.